Personalized Health Care (PHC) in Cancer - Genomic Biomarkers for Pharmaceutical Development - page 47

[94] Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and beneit of chemotherapy in women
with node-negative, ER-positive breast cancer. J Clin Oncol 2006;24:3726-34.
[95] Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive
value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-recep-
tor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol
2010;11:55-65.
[96] Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, et al. The effect of Oncotype DX recurrence score
on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and cor-
relation with estimation of recurrence risk by breast cancer specialists. Oncologist 2011;16(11):1520-6.
[97] Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, et al. Utility of
oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II,
lymph node-negative breast cancers. Cancer 2010;116(22):5161-7.
[98] Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-
treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
[99] Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evalu-
ating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-
positive tumors. N Engl J Med 1989;320:479-84.
[100] Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer
2006;7:347-50.
[101] Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, et al. The 70-gene signa-
ture as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat
2010;119:551-8.
[102] Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, et al. The predictive value
of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat
2010;120:655-61.
[103] van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression proiling predicts
clinical outcome of breast cancer. Nature 2002;415:530-6.
[104] Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microar-
ray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278.
[105] Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, et al. Analysis of the MammaPrint breast
cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008;14:2988-93.
[106] Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E, TRANSBIG Consortium, The MINDACT trial: the irst
prospective clinical validation of a genomic tool. Mol Oncol 2007;1:246-51.
[107] Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer
trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86(1):97-100.
[108] Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocar-
cinomas to geitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med
2005;2:e73.
[109] Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9.
[110] Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, et al. Analysis of epidermal growth factor recep-
tor gene mutation in patients with non-small cell lung cancer and acquired resistance to geitinib. Clin
Cancer Res 2006;12:5764-9.
[111] Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, et al. Noninvasive detection of EGFR
T790M in geitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009;15:2630-6.
[112] Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Grifin JD. Second generation inhibitors of BCR-ABL
for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56.
[113] Breccia M. Hematology: nilotinib and dasatinib - new 'magic bullets' for CML? Nat Rev Clin Oncol
2010;7:557-8.
[114] Fuerst ML. FDA approves dasatinib for imatinib resistance and intolerance 3 weeks after enthusiastic recom-
mendation from ODAC. Oncol Times 2006;28:9-10.
[115] Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly
diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.